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Loss of BRCA1 has been shown to expand breast stem cells. In Nature Medicine, Lim et al. (2009) demon-
strate that breast tissue from BRCA1 mutation carriers contains expanded luminal progenitor cells, suggest-
ing a broader role for BRCA1 in mammary development.
Cell Stem Cell
PreviewsWomen that harbor germline mutations of
BRCA1 experience up to an 80% lifetime
risk of developing breast cancer (Narod
and Foulkes, 2004). The majority of these
breast cancers are of the ‘‘basal’’ sub-
type, which are characterized by the lack
of expression of estrogen and proges-
terone receptors (ER/PRs) and the ab-
sence of elevated levels of the EGF family
receptor ERBB2/Her2 (Turner and Reis-
Filho, 2006). It has been postulated that
these tumors may arise from ER/PR-
negative, normal breast stem cells. How-
ever, a recent publication by Lim et al.
(2009) in Nature Medicine has questioned
the origin of BRCA1-deficient breast tu-
mors (Lim et al., 2009). Using cell-surface
protein markers (CD49f, EpCAM) first
characterized in mouse mammary tissue
(Stingl et al., 2006), the authors demon-
strate that functional stem (CD49fhi,
EpCAM), luminal progenitor (CD49f+,
EpCAM+), and more differentiated mam-
mary cells (CD49f, EpCAM) can be
isolated from normal human breast tis-
sue. Interestingly, they demonstrate that
breast tissue isolated from women who
carry germline mutations of BRCA1 con-
tain expanded populations of luminal pro-
genitor cells. Furthermore, the gene ex-
pression profile of this tissue as well as
that obtained from sporadic ‘‘basal’’
breast cancer most closely resembles the
signature expressed by normal luminal
progenitor cells. On the basis of these
observations, Lim et al. suggest that the
aberrant luminal progenitors are the target
population for basal tumor development
in BRCA1 mutation carriers. Elucidating
the cell of origin of BRCA1-deficient and
basal cancers is of more than academic
interest because these studies haveimportant implications for the develop-
ment of breast cancer prevention and
treatment strategies.
Dosage Effects of BRCA1
Expression Level on Mammary
Stem and Luminal Progenitor Cell
Differentiation
On the surface, Lim et al. (2009) may
appear to contradict findings from our
group that have suggested that BRCA1
regulates human mammary epithelial cell
development at the stem cell level (Liu
et al., 2008); such a role by BRCA1 is a
concept proposed by Narod and Foulkes
(2004). However, when interpreting both
sets of studies, it is important to consider
the potential role of gene dosage in regu-
lating mammary differentiation. For ex-
ample, in Lim et al. (2009), tissue was
obtained from BRCA1 mutation carriers
who are haplo insufficient. Therefore,
these samples carry one normal and one
mutated allele of BRCA1, resulting in the
expression of50% of the normal protein
level. In Liu et al. (2008), we demonstrated
that complete knockdown of BRCA1
expression in normal human mammary
cells with a BRCA1 siRNA lentivirus
expanded the population of cells express-
ing the stem cell marker Aldehyde dehy-
drogenase (ALDH), as assessed by the
ALDEFLUOR assay (Ginestier et al.,
2007). These stem/progenitor cells were
ER negative and expressed mesen-
chymal markers such as vimentin. The
clinical relevance of these findings was
demonstrated by the detection of
ALDH1-positive acini in breast tissue
from BRCA1 mutation carriers. Interest-
ingly, we demonstrated loss of heterozy-
gocity (LOH) for the normal BRCA1 alleleCell Stem Cell 5,in these ALDH1-expressing cell clusters
but not in adjacent ALDH1-negative acini
(Liu et al., 2008). Together, these observa-
tions combined with those of Lim et al.
(2009) suggest that the effects of BRCA1
on mammary differentiation may be dose
dependent, in that a partial loss may block
differentiation at the luminal progenitor
stage, whereas a more complete loss of
activity leads to stem cell expansion
(Figure 1). This model is also supported
by other data from the Lim et al. study,
which observed the lowest expression of
BRCA1 in breast stem cells, an interme-
diate level in luminal progenitors, and the
highest levels in differentiated luminal
mammary cells. The observation that the
majority of breast tumors from BRCA1
mutation carriers display LOH at the
BRCA1 locus and are ER/PR negative is
also consistent with this model. Finally,
the data of Lim et al. (2009) indicate
that BRCA1 haplo-insufficient cells dis-
play phenotypic alterations on the ba-
sis of their cell-surface marker expres-
sion, despite the fact that the tissue
sections themselves appear histologically
normal.
MouseModels of BRCA1 Deficiency
Although mouse models of BRCA1 defi-
ciency have been highly informative, it is
important to distinguish between different
models when interpreting the data they
produce. In the MMTV-Cre;BRCA1f11/f11;
p53f5&6/f5&6 model, utilized by Poole et al.
(2006), Cre recombinase is driven by the
MMTV promoter that is primarily ex-
pressed in more differentiated luminal
cell populations. Unlike the breast cancer
that develops in most human BRCA1 mu-
tation carriers, the breast cancers thatSeptember 4, 2009 ª2009 Elsevier Inc. 229
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Previewsdevelop in this model are ER/
PR positive (Poole et al.,
2006). In contrast, when Cre
recombinase is driven by
the cytokeratin 14 promoter
(K14cre;BRCA1F/+;p53F/F con-
struct) that is expressed in
more primitive cells, BRCA1
deletion generates ER/PR-
negative breast tumors (Liu
et al., 2007). This observation
suggests that the state of
mammary differentiation at
which BRCA1 is lost may
determine the cellular pheno-
type of resulting tumors and
may account for the differ-
ences between ER-positive
and -negative cancers found
in BRCA1-deficient tumors.
Interestingly, Lim et al. ob-
served heterogeneity within
the luminal progenitor cell
pool, which contains both
ER-positive and ER-negative
cells. Further investigation will be needed
to determine whether both luminal
progenitor subpopulations are equally
expanded in breast epithelium from
BRCA1 mutation carriers. The important
role of BRCA1 in DNA replication
suggests that expanded stem and/or
luminal progenitor populations that have
lost BRCA1 expression may serve as
targets for further mutational events. In
addition, these studies emphasize that
both the cell of origin as well as its muta-
tion profile may contribute to the genetic
and clinical heterogeneity of human
breast cancer and highlight that thera-
peutic strategies may need to be tailored
to specific disease subtypes.
Cellular Origin of ‘‘Basal’’ Breast
Cancers
Finally, Lim et al. report that the gene ex-
pressionprofileofnormalbreastepithelium
from BRCA1 mutation carriers or cancer
cells from sporadic ‘‘basal tumors’’ resem-
bles that of luminal progenitor cells. This is
an intriguing observation but does not
directly address the question of the cellular
origin of these tumors or whether they
contain cellular subpopulations with
distinct characteristics. Recent research
has suggested that breast tumors may
contain and be driven by a cellular subpop-
ulation with tumor-initiating or ‘‘stem cell’’
characteristics. These cells, by virtue of
their resistance to chemotherapy and
radiotherapy, may contribute to treatment
relapse and metastasis (Wicha et al.,
2006). In support of this model, recent
studies that examined the gene expression
profile of breast tumors before and after
neoadjuvant chemotherapy or hormonal
therapy revealed that the gene expression
signature in the residual surviving cells of
both basal and luminal tumors resembles
that of ‘‘cancer stem cells’’ (Creighton
et al., 2009). Furthermore, consistent with
Lim et al. (2009), this pattern of gene
expression resembles the profile recently
described as ‘‘claudin low,’’ a molecular
subtype of breast cancer that is ER
negative but that expresses a number of
mesenchymal markers such as vimentin.
Interestingly, we have found that human
mammary xenografts derived from
BRCA1 knockdown cells displayed a
similar phenotype (Liu et al., 2008).
Lim et al.’s finding that basal tumors ex-
pressed a predominant gene pattern
resembling luminal progenitors suggests
that the majority of cells in these tumors
are arrested at this stage of development.
Future studies will be needed to
address the functional impor-
tance of individual subpopula-
tions of cells in these tumors.
An understanding of the
pathways that regulate self-
renewal and differentiation of
mammary stem and progen-
itor cells may shed light on
how alterations in these path-
ways generate the diverse
molecular subtypes of human
breast cancer. Studies such
as the one reported by Lim
et al. provide important in-
sights into these processes
and may suggest new strate-
gies for breast cancer preven-
tion and treatment.
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Figure 1. Role of BRCA1 in Mammary Development
BRCA1 expression is low in mammary stem cells and progressively increases
during differentiation (left). Loss of one copy of BRCA1 in BRCA1 mutation
carriers results in expansion of the luminal progenitor population (middle),
whereas complete loss of BRCA1 expression expands the stem/early progen-
itor population (right). Stem cell/differentiation markers and their abbreviations
are defined as follows: CD49f, a6 integrin; ESA, epithelial specific antigen
(EpCAM); CD10, membrane metallo-endopeptidase; ALDEFLUOR, aldehyde
dehydrogenase activity; and ER, estrogen receptor.230 Cell Stem Cell 5, September 4, 2009 ª2009 Elsevier Inc.
